LEMTRADA Pregnancy Registry in Multiple Sclerosis
International LEMTRADA Pregnancy Exposure Cohort in Multiple Sclerosis
Sponsor: Genzyme, a Sanofi Company
Terminated
The sponsor stopped the study due to low recruitment with no safety concerns
Other terminated trials from Genzyme, a Sanofi Company
Other Multiple Sclerosis trials with similar outcome
Listed as NCT03774914, this observational or N/A phase trial focuses on Multiple Sclerosis and remains terminated or withdrawn. Sponsored by Genzyme, a Sanofi Company, it has been updated 11 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Terminated
-
Sep 2024 — Sep 2025 [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
May 2022 — Jul 2024 [monthly]
Terminated
-
Feb 2022 — May 2022 [monthly]
Terminated
Status: Active Not Recruiting → Terminated
▶ Show 6 earlier versions
-
Nov 2021 — Feb 2022 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Mar 2021 — Nov 2021 [monthly]
Recruiting
-
Feb 2021 — Mar 2021 [monthly]
Recruiting
-
Jan 2021 — Feb 2021 [monthly]
Recruiting
-
Sep 2019 — Jan 2021 [monthly]
Recruiting
-
Jan 2019 — Sep 2019 [monthly]
Recruiting
First recorded
Sep 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genzyme, a Sanofi Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aarhus C, Denmark , Bochum, Germany , Box Hill, Australia , Canada, Canada , Charleroi, Belgium , Gallarate (VA), Italy , Gothenburg, Sweden , Linz, Austria , Netherlands, Netherlands , New York, United States and 3 more locations